Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Antibody-Drug combo aims to tackle tough lymphoma

NCT ID NCT05139017

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 14 times

Summary

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination or standard chemo alone. The main goals are to see if the combo improves how long people live without their cancer getting worse, and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zilovertamab vedotin (an antibody-drug conjugate) combined with standard chemotherapy drugs (rituximab, gemcitabine, oxaliplatin, or bendamustine)
What this could lead to
If successful, this combination could offer a new treatment option for people with relapsed or refractory diffuse large B-cell lymphoma, potentially slowing disease progression.
What could go wrong
This is an early-to-mid-stage trial (phase 2/3) with only 290 participants. The drug may cause side effects like infusion reactions or low blood counts, and it may not prove more effective than current standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 290 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has a histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL). * Has radiographically measurable DLBCL per the Lugano Response Criteria, as assessed locally by the investigator. * Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 within 7 days prior to study treatment initiation. * Has adequate organ function. * Is able to provide new or archival tumor tissue sample not previously irradiated. Zilovertamab vedotin plus R-GemOx, or R-GemOx study arms: * Has relapsed or refractory DLBCL and is ineligible for or have failed autologous stem-cell transplant (ASCT) and have failed at least 1 line of prior therapy. * Has post-chimeric antigen receptor T (post-CAR-T) cell therapy failure or is ineligible for CAR-T cell therapy. Not applicable with protocol amendment 4: Zilovertamab vedotin plus Bendamustine Rituximab (BR), and Bendamustine Rituximab study arms: * Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and have failed at least 2 lines of prior therapy. * Has post-CAR-T therapy failure or is ineligible for CAR-T cell therapy. Exclusion Criteria: * Not applicable with protocol amendment 4: Has history of transformation of indolent disease to DLBCL * Has received solid organ transplant at any time. * Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL). * Has clinically significant (ie, active) cardiovascular disease or serious cardiac arrhythmia requiring medication. * Has ongoing graft-versus-host disease (GVHD) of any grade, or is receiving treatment for their GVHD. * Has clinically significant pericardial or pleural effusion. * Has ongoing Grade \>1 peripheral neuropathy. * Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * Has a demyelinating form of Charcot-Marie-Tooth disease. * Has contraindication to any of the study intervention components including but not limited to prior anaphylactic reaction. * Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention. * Has received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. * Has ongoing corticosteroid therapy. * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. * Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. Participants with prior CNS involvement are eligible if their CNS disease is in radiographic, cytological (for cerebrospinal fluid disease), and clinical remission. * Has an active infection requiring systemic therapy. * Has a known history of human immunodeficiency virus (HIV) infection. * Has a known active Hepatitis C virus infection. * Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma DLBCL

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    55 sites in 12 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aarhus Universitetshospital, Skejby ( Site 1701)

    RECRUITING

    Aarhus, Central Jutland, 8200, Denmark

  • Aberdeen Royal Infirmary ( Site 2104)

    COMPLETED

    Aberdeen, Aberdeen City, AB25 2ZN, United Kingdom

  • Alliance Cancer Specialists (ACS) ( Site 8001)

    RECRUITING

    Horsham, Pennsylvania, 19044, United States

  • Ankara University Hospital Cebeci-hematology ( Site 1901)

    RECRUITING

    Ankara, 06100, Turkey (Türkiye)

  • Aotearoa Clinical Trials ( Site 0501)

    ACTIVE_NOT_RECRUITING

    Auckland, 2025, New Zealand

  • Atlantic Health System ( Site 0116)

    COMPLETED

    Morristown, New Jersey, 07960, United States

  • BRP-Hialeah Hospital ( Site 0182)

    RECRUITING

    Hialeah, Florida, 33013, United States

  • Bass Medical Group ( Site 0166)

    RECRUITING

    Walnut Creek, California, 94598, United States

  • Beijing Cancer hospital ( Site 3000)

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Beverly Hills Cancer Center ( Site 0184)

    ACTIVE_NOT_RECRUITING

    Beverly Hills, California, 90211, United States

  • Biocenter ( Site 2401)

    RECRUITING

    Concepción, Biobio, 4070196, Chile

  • Blue Ridge Cancer Care ( Site 0169)

    ACTIVE_NOT_RECRUITING

    Roanoke, Virginia, 24014, United States

  • Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163)

    RECRUITING

    Boca Raton, Florida, 33486, United States

  • Bradfordhill ( Site 2403)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • CELAN,S.A ( Site 2603)

    ACTIVE_NOT_RECRUITING

    Guatemala City, 1010, Guatemala

  • CIMCA ( Site 2501)

    RECRUITING

    San José, 10103, Costa Rica

  • Carmel Hospital ( Site 1103)

    COMPLETED

    Haifa, 3436212, Israel

  • Centro de Infusion Superare ( Site 2701)

    COMPLETED

    Mexico City, 03104, Mexico

  • Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304)

    COMPLETED

    Lublin, Lublin Voivodeship, 20-090, Poland

  • Chongqing University Cancer Hospital-Medical Oncology ( Site 3025)

    ACTIVE_NOT_RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • Chongqing University Three Gorges Hospital ( Site 3026)

    ACTIVE_NOT_RECRUITING

    Chongqing, Chongqing Municipality, 404199, China

  • Chulalongkorn University ( Site 0402)

    ACTIVE_NOT_RECRUITING

    Pathumwan, Bangkok, 10330, Thailand

  • Clermont Oncology Center ( Site 0174)

    RECRUITING

    Clermont, Florida, 34711, United States

  • Clínica Inmunocel ( Site 2404)

    RECRUITING

    Santiago, Region M. de Santiago, 7580206, Chile

  • Clínica RedSalud Vitacura ( Site 2409)

    RECRUITING

    Santiago, Region M. de Santiago, 7650018, Chile

  • Clínica San Felipe ( Site 2805)

    ACTIVE_NOT_RECRUITING

    Lima, 15072, Peru

  • Clínicas AUNA Sede Chiclayo ( Site 2803)

    ACTIVE_NOT_RECRUITING

    Chiclayo, Lambayeque, 14001, Peru

  • Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004)

    ACTIVE_NOT_RECRUITING

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76008, Ukraine

  • Comprehensive Cancer Centers of Nevada ( Site 0168)

    RECRUITING

    Las Vegas, Nevada, 89169, United States

  • Corewell Health ( Site 0162)

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Dana-Farber Cancer Institute-Lymphoma ( Site 0111)

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02215, United States

  • Dokuz Eylül Üniversitesi-Hematology ( Site 1905)

    RECRUITING

    Izmir, 35340, Turkey (Türkiye)

  • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912)

    RECRUITING

    Yenimahalle, Ankara, 06200, Turkey (Türkiye)

  • Ege University Medicine of Faculty ( Site 1902)

    RECRUITING

    Bornova, İzmir, 35100, Turkey (Türkiye)

  • Emek Medical Center-Hematology Unit ( Site 1102)

    COMPLETED

    Afula, 1834111, Israel

  • Evangelismos General Hospital of Athens ( Site 0900)

    ACTIVE_NOT_RECRUITING

    Athens, Attica, 106 76, Greece

  • FALP-UIDO ( Site 2400)

    COMPLETED

    Santiago, Region M. de Santiago, 7500921, Chile

  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801)

    ACTIVE_NOT_RECRUITING

    Bogotá, Bogota D.C., 110131, Colombia

  • Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400)

    ACTIVE_NOT_RECRUITING

    Bangkok, Bangkok, 10700, Thailand

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204)

    COMPLETED

    Roma, 00168, Italy

  • Fudan University Shanghai Cancer Center ( Site 3009)

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Fukushima Medical University Hospital ( Site 3207)

    RECRUITING

    Fukushima, 960-1295, Japan

  • Fundacion Valle del Lili ( Site 0802)

    RECRUITING

    Cali, Valle del Cauca Department, 760032, Colombia

  • Grampians Health ( Site 1802)

    RECRUITING

    Ballarat, Victoria, 3350, Australia

  • Hadassah Medical Center ( Site 1100)

    COMPLETED

    Jerusalem, 9112001, Israel

  • Health Pharma Professional Research S.A. de C.V: ( Site 2700)

    COMPLETED

    Mexico City, Mexico City, 03100, Mexico

  • Henan Cancer Hospital-hematology department ( Site 3013)

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Hokkaido University Hospital ( Site 3202)

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Hospital Aleman ( Site 2200)

    ACTIVE_NOT_RECRUITING

    Buenos Aites, Buenos Aires F.D., C1118AAT, Argentina

  • Hospital Erasto Gaertner ( Site 2302)

    RECRUITING

    Curitiba, Paraná, 81520-060, Brazil

  • Hospital Italiano de Buenos Aires ( Site 2203)

    ACTIVE_NOT_RECRUITING

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1199ABB, Argentina

  • Hospital Metropolitano - Sede Lindora ( Site 2500)

    ACTIVE_NOT_RECRUITING

    Santa Ana, Provincia de San José, 10903, Costa Rica

  • Hospital Nacional Dos De Mayo ( Site 2804)

    RECRUITING

    Lima, 15087, Peru

  • Hospital Nacional Edgardo Rebagliati Martins ( Site 2802)

    ACTIVE_NOT_RECRUITING

    Lima, 15072, Peru

  • Hospital Pablo Tobon Uribe ( Site 0804)

    RECRUITING

    Medellín, Antioquia, 50034, Colombia

  • Hospital Paulistano ( Site 2300)

    ACTIVE_NOT_RECRUITING

    São Paulo, 01321-001, Brazil

  • Hospital Privado Universitario de Córdoba ( Site 2202)

    ACTIVE_NOT_RECRUITING

    Córdoba, Córdoba Province, X5016KEH, Argentina

  • Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203)

    ACTIVE_NOT_RECRUITING

    Rozzano, Milano, 20089, Italy

  • IC La Serena Research ( Site 2405)

    ACTIVE_NOT_RECRUITING

    La Serena, Coquimbo Region, 1720430, Chile

  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 2800)

    ACTIVE_NOT_RECRUITING

    Surquillo, Muni Metro de Lima, 15038, Peru

  • IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200)

    COMPLETED

    Bologna, 40138, Italy

  • Illinois Cancer Specialists ( Site 8000)

    RECRUITING

    Niles, Illinois, 60714, United States

  • Innovative Clinical Research Institute ( Site 0122)

    COMPLETED

    Whittier, California, 90603, United States

  • Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002)

    ACTIVE_NOT_RECRUITING

    Lviv, Lviv Oblast, 79057, Ukraine

  • Instituto Alexander Fleming ( Site 2201)

    ACTIVE_NOT_RECRUITING

    CABA, C1426ANZ, Argentina

  • Instituto Médico de Alta Tecnologia S.A.S ( Site 0803)

    ACTIVE_NOT_RECRUITING

    Montería, Departamento de Córdoba, 230002, Colombia

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205)

    COMPLETED

    Mar del Plata, Buenos Aires, B7600FZO, Argentina

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202)

    ACTIVE_NOT_RECRUITING

    Naples, 80131, Italy

  • Jiangxi Provincial Cancer Hospital ( Site 3005)

    RECRUITING

    Nanchang, Jiangxi, 330029, China

  • Kansai Medical University Hospital ( Site 3203)

    RECRUITING

    Hirakata, Osaka, 573-1191, Japan

  • Liga Norte Riograndense Contra o Câncer ( Site 2305)

    ACTIVE_NOT_RECRUITING

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • MEDI-K ( Site 2602)

    ACTIVE_NOT_RECRUITING

    Guatemala City, 01009, Guatemala

  • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000)

    ACTIVE_NOT_RECRUITING

    Cherkasy, Cherkasy Oblast, 18009, Ukraine

  • Maharaj Nakorn Chiang Mai Hospital ( Site 0401)

    ACTIVE_NOT_RECRUITING

    Muang, Chiang Mai, 50200, Thailand

  • Medivest Centro de Investigación Integral ( Site 2704)

    COMPLETED

    Chihuahua City, 31203, Mexico

  • Mega Medipol-Hematology ( Site 1909)

    RECRUITING

    Istanbul, 34214, Turkey (Türkiye)

  • Mie University Hospital ( Site 3210)

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300)

    ACTIVE_NOT_RECRUITING

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • National Hospital Organization Kyushu Cancer Center ( Site 3204)

    RECRUITING

    Fukuoka, 811-1395, Japan

  • National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005)

    COMPLETED

    Kyiv, 03115, Ukraine

  • New York Medical College ( Site 0113)

    RECRUITING

    Valhalla, New York, 10595, United States

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133)

    ACTIVE_NOT_RECRUITING

    Louisville, Kentucky, 40207, United States

  • Oncocentro Valdivia ( Site 2407)

    RECRUITING

    Valdivia, Los Ríos Region, 5112129, Chile

  • Oncologos del Occidente ( Site 0800)

    ACTIVE_NOT_RECRUITING

    Pereira, Risaralda Department, 660001, Colombia

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177)

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188)

    RECRUITING

    Grand Island, Nebraska, 68803, United States

  • Ondokuz Mayıs Universitesi ( Site 1907)

    COMPLETED

    Samsun, 55139, Turkey (Türkiye)

  • Osaka Metropolitan University Hospital ( Site 3205)

    RECRUITING

    Osaka, 545-8586, Japan

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)

    RECRUITING

    Glendale, Arizona, 85304, United States

  • Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700)

    ACTIVE_NOT_RECRUITING

    Paris, 75013, France

  • Pratia MCM Krakow ( Site 1303)

    ACTIVE_NOT_RECRUITING

    Krakow, Lesser Poland Voivodeship, 30-727, Poland

  • Pratia Onkologia Katowice ( Site 1306)

    ACTIVE_NOT_RECRUITING

    Katowice, Silesian Voivodeship, 40-519, Poland

  • Presbyterian Rust Jorgensen Cancer ( Site 9506)

    ACTIVE_NOT_RECRUITING

    Rio Rancho, New Mexico, 87124, United States

  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)

    COMPLETED

    Toronto, Ontario, M5G 2M9, Canada

  • Princess Margaret Hospital ( Site 3101)

    ACTIVE_NOT_RECRUITING

    Hong Kong, Hong Kong

  • Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601)

    ACTIVE_NOT_RECRUITING

    Guatemala City, 01010, Guatemala

  • Queen Mary Hospital ( Site 3100)

    ACTIVE_NOT_RECRUITING

    Hong Kong, 000000, Hong Kong

  • Regional General Hospital of Athens "Laiko" ( Site 0901)

    ACTIVE_NOT_RECRUITING

    Athens, Attica, 115 26, Greece

  • Royal Perth Hospital-Haematology ( Site 1801)

    RECRUITING

    Perth, Western Australia, 6000, Australia

  • Saint Elizabeth Medical Center Edgewood ( Site 0165)

    RECRUITING

    Edgewood, Kentucky, 41017, United States

  • Samsung Medical Center ( Site 0300)

    COMPLETED

    Seoul, 06351, South Korea

  • Seoul National University Hospital-Oncology ( Site 0302)

    ACTIVE_NOT_RECRUITING

    Seoul, 03080, South Korea

  • Sichuan Cancer hospital-Oncology ( Site 3021)

    ACTIVE_NOT_RECRUITING

    Chengdu, Sichuan, 610041, China

  • Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305)

    ACTIVE_NOT_RECRUITING

    Wałbrzych, Lower Silesian Voivodeship, 58-309, Poland

  • St. Vincent Frontier Cancer Center-Research ( Site 0108)

    RECRUITING

    Billings, Montana, 59102, United States

  • State non-profit enterprise National Cancer Institute ( Site 2001)

    ACTIVE_NOT_RECRUITING

    Kyiv, 03022, Ukraine

  • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001)

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510060, China

  • Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302)

    COMPLETED

    Gdynia, Pomeranian Voivodeship, 81-519, Poland

  • Tennessee Cancer Specialists ( Site 7000)

    RECRUITING

    Knoxville, Tennessee, 37909, United States

  • The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027)

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029)

    ACTIVE_NOT_RECRUITING

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Nanchang University ( Site 3004)

    ACTIVE_NOT_RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The First Hospital of Jilin University-Hematology ( Site 3012)

    RECRUITING

    Changchun, Jilin, 130021, China

  • The Jikei University Hospital ( Site 3208)

    RECRUITING

    Minato, Tokyo, 105-8471, Japan

  • The Royal Cornwall Hospital ( Site 2103)

    COMPLETED

    Truro, England, TR1 3LJ, United Kingdom

  • Tokai University Hospital ( Site 3212)

    RECRUITING

    Isehara, Kanagawa, 259-1193, Japan

  • Tokyo Metropolitan Komagome Hospital ( Site 3200)

    RECRUITING

    Bunkyo, Tokyo, 113-8677, Japan

  • Townsville University Hospital ( Site 1800)

    ACTIVE_NOT_RECRUITING

    Townsville, Queensland, 4814, Australia

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017)

    RECRUITING

    Wuhan, Hubei, 430048, China

  • University College London Hospital-Cancer Clinical Trials Unit ( Site 2100)

    COMPLETED

    London-Camden, London, City of, NW1 2PG, United Kingdom

  • University Hospital of Alexandroupolis ( Site 0903)

    ACTIVE_NOT_RECRUITING

    Alexandroupoli, East Macedonia and Thrace, 681 00, Greece

  • University Hospital,Kyoto Prefectural University of Medicine ( Site 3209)

    RECRUITING

    Kyoto, 602-8566, Japan

  • University of Kentucky Chandler Medical Center ( Site 0158)

    ACTIVE_NOT_RECRUITING

    Lexington, Kentucky, 40536, United States

  • University of Maryland ( Site 0123)

    ACTIVE_NOT_RECRUITING

    Baltimore, Maryland, 21201, United States

  • University of Massachusetts Medical School ( Site 0119)

    ACTIVE_NOT_RECRUITING

    Worcester, Massachusetts, 01655, United States

  • University of Miyazaki Hospital ( Site 3211)

    RECRUITING

    Miyazaki, 889-1692, Japan

  • University of Yamanashi Hospital ( Site 3201)

    RECRUITING

    Chūō, Yamanashi, 409-3898, Japan

  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301)

    COMPLETED

    Wroclaw, Lower Silesian Voivodeship, 50-367, Poland

  • Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156)

    COMPLETED

    Nashville, Tennessee, 37232, United States

  • West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016)

    ACTIVE_NOT_RECRUITING

    Chengdu, Sichuan, 610041, China

  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309)

    RECRUITING

    Słupsk, Pomeranian Voivodeship, 76-200, Poland

  • Yamagata University Hospital ( Site 3206)

    RECRUITING

    Yamagata, 990-9585, Japan

  • Zhejiang Cancer Hospital ( Site 3014)

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

  • Zhujiang Hospital ( Site 3002)

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510280, China

  • centre hospitalier lyon sud-Service Hématologie ( Site 0702)

    ACTIVE_NOT_RECRUITING

    Pierre-Bénite, Rhone, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.